Dr. Chang H. Ahn is an internationally recognized drug development expert with over 20 years of experience in the fields of cancer and biotechnology. He founded Rexahn Pharmaceuticals, Inc. in 2001, and currently serves as the company's Chairman and CEO.
Prior to founding Rexahn, Dr. Ahn held dual positions as both Expert Regulatory Officer and Lab Chief at the Food and Drug Administration (FDA)'s Center for Drug Evaluation and Research. While at the FDA, Dr. Ahn represented the agency in the fields of Antisense Oligonucleotide Therapeutics and Multi-Drug Resistance, and served a key role as both author and co-author of several FDA guidance documents. Before joining the FDA, Dr. Ahn carried out cancer research at the National Cancer Institute of the NIH, as well as at Emory University's School of Medicine.
In 2003 and 2004, Dr. Ahn organized and chaired the U.S.-Korea Bio Business and Partnership Forum, for which Korean government and Maryland State were partners. He served as the Overseas Organizing Chairman of the Osong International BioExpo in 2002. He has served as President of the Society of Biomedical Research during 2000-2004. He has also served as Editor-In-Chief, Editor and Review Editor of Journal of Biomedical Research, BioFocus and Archives of Pharmacal Research, respectively.
Dr. Ahn was named as the Maryland's Top 25 CEOs to know by the Gazette newspaper in 2006. Dr. Ahn is an inventor of several US patents for unmet medical needs. One of the invention, Archexin, has been names as "100 Great Investigational Drugs" in the world in 2007 by R&D Directions.
Dr. Ahn has been recognized by Who's Who in America (Marquis), Who's Who in America-Science and Engineering (Millennium-5th edition, Marquis), International Directory of Distinguished Leadership (American Biographical Institute), Who's Who in Executives and Professional (National Register), and Who's Who (Strathmore).
Dr. Ahn acquired his Ph.D. in pharmacology from the Ohio State University. He also holds two B.S. degrees in pharmacy from Creighton University and Seoul National University.